# EDGAR Filing Document

**Accession Number:** 0000812796
**File Stem:** 0000000000-25-009452
**Filing Date:** 2025-9
**Character Count:** 2667
**Document Hash:** ca0d9149fc337c5e22d9af6659dbc096
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009452.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0000000000-25-009452

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250902

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLIGENIX, INC.
- **CENTRAL INDEX KEY:** 0000812796
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411505029
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08384

**BUSINESS ADDRESS:**
- **STREET 1:** 29 EMMONS DRIVE
- **STREET 2:** SUITE B-10
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 609-538-8200

**MAIL ADDRESS:**
- **STREET 1:** 29 EMMONS DRIVE
- **STREET 2:** SUITE B-10
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DOR BIOPHARMA INC
- **DATE OF NAME CHANGE:** 20020329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ENDOREX CORP
- **DATE OF NAME CHANGE:** 19960916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMMUNOTHERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19920703
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-083947

## Text-Extract

```

                                                            September 2, 2025

Christopher Schaber
Chief Executive Officer
Soligenix, Inc.
29 Emmons Drive, Suite B-10
Princeton, NJ 08540

       Re: Soligenix, Inc.
           Draft Registration Statement on Form S-1
           Submitted August 27, 2025
           CIK No. 0000812796
Dear Christopher Schaber:

       This is to advise you that we do not intend to review your registration
statement.

        We request that you publicly file your registration statement and
non-public draft
submission on EDGAR at least two business days prior to the requested effective
date and
time. Please refer to Rules 460 and 461 regarding requests for acceleration. We
remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Tyler Howes at 202-551-3370 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Driscoll R. Ugarte, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._